Results 231 to 240 of about 3,476,529 (285)

Background incidence rates and observed-to-expected ratios of adverse events of special interest after covid-19 mRNA vaccination during pregnancy in France: a nationwide population-based study. [PDF]

Lancet Reg Health Eur
Escolano S, Quentin E, Demailly R, Ahmed I, Tubert-Bitter P.   +4 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Intolerance of uncertainty in adolescents with and without social communication disorder: group and gender differences. [PDF]

Front Psychiatry
Azizpour A, Alamdarloo GH, Shojaei S, Moradi S.   +3 more
europepmc   +1 more source

Emergency medical preparedness and response for mass gatherings: Papua New Guinea emergency medical team's experience during Pope Francis's 2024 visit. [PDF]

Western Pac Surveill Response J
Oli U, Nou GG, Hosea R, Konigala K.
europepmc   +1 more source

Special Events

GSA Today, 2005
openaire   +1 more source

Safety and effectiveness of selpercatinib in patients with RET fusion-positive non-small cell lung cancer in real-world clinical practice: a postmarketing study in Japan. [PDF]

Jpn J Clin Oncol
Chen Y, Mori J, Wakabayashi S, Urayama KY.   +3 more
europepmc   +1 more source

Analysis of Onset Timing and Risk Factors for Mesalazine-related Adverse Events Using the JADER Database. [PDF]

In Vivo
Iwayama K, Manabe T, Arai Y, Wakata Y, Oikawa G, Yamamoto M, Soma M, Ohtaki KI, Konda A, Machida M.   +9 more
europepmc   +1 more source

Adverse drug reaction reporting and monitoring: A review of global practices. [PDF]

Bioinformation
Mohsin N, Alyami AM, Al Shermah IM, Al Shermah AM, Alharthi KM, Alyami TM, Almakrami HA, Mohammed Muqmish HH, Ali Sarrar IJ.   +8 more
europepmc   +1 more source

Tislelizumab combined with gemcitabine plus cisplatin for muscle-invasive upper tract urothelial carcinoma: A retrospective single-center cohort analysis. [PDF]

J Int Med Res
Zhang J, Xiao Y, Cai D, Zhu H, Zhong W.
europepmc   +1 more source